Deep brain stimulation targeting the fornix for mild Alzheimer dementia: design of the ADvance randomized controlled trial

References

• Lanctôt KL, Rajaram RD, Herrmann N. Therapy for Alzheimer’s disease: how effective are current treatments? Ther Adv Neurol Disord. 2009;2(3):163–180.
   PubMedGoogle Scholar
• Latest Facts and Figures Report. 2014. Accessed October 1, 2014.
   Google Scholar
• Wimo A, Prince M. World Alzheimer Report 2010: The Global Economic Impact of Dementia. London, United Kingdom: Alzheimer’s Disease International (ADI); 2010.
   Google Scholar
• Aisen PS, Saumier D, Briand R, et al. A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006;67(10):1757–1763.
   PubMed Web of Science ®Google Scholar
• Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372(9634):207–215.
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73(24):2061–2070.
   PubMed Web of Science ®Google Scholar
• Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302(23):2557–2564.
   PubMed Web of Science ®Google Scholar
• Andrews-Hanna JR, Snyder AZ, Vincent JL, et al. Disruption of large-scale brain systems in advanced aging. Neuron. 2007;56(5):924–935.
   PubMed Web of Science ®Google Scholar
• Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer’s disease. J Neurosci. 2009;29(6):1860–1873.
   PubMed Web of Science ®Google Scholar
• Davis KD, Kiss ZH, Luo L, Tasker RR, Lozano AM, Dostrovsky JO. Phantom sensations generated by thalamic microstimulation. Nature. 1998;391(6665):385–387.
   PubMed Web of Science ®Google Scholar
• Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med. 2001;345(13):956–963.
   PubMed Web of Science ®Google Scholar
• Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63–73.
   PubMed Web of Science ®Google Scholar
• Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry. 2008;64(6):461–467.
   PubMed Web of Science ®Google Scholar
• Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651–660.
   PubMed Web of Science ®Google Scholar
• Laxton AW, Tang-Wai DF, McAndrews MP, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease. Ann Neurol. 2010;68(4):521–534.
   PubMed Web of Science ®Google Scholar
• Hopper MW, Vogel FS. The limbic system in Alzheimer’s disease. A neuropathologic investigation. Am J Pathol. 1976;85(1):1–20.
   Web of Science ®Google Scholar
• Yasmin H, Aoki S, Abe O, et al. Tract-specific analysis of white matter pathways in healthy subjects: a pilot study using diffusion tensor MRI. Neuroradiology. 2009;51(12):831–840.
   PubMed Web of Science ®Google Scholar
• Rudebeck SR, Scholz J, Millington R, Rohenkohl G, Johansen-Berg H, Lee AC. Fornix microstructure correlates with recollection but not familiarity memory. J Neurosci. 2009;29(47):14987–14992.
   PubMed Web of Science ®Google Scholar
• Gaffan EA, Gaffan D, Hodges JR. Amnesia following damage to the left fornix and to other sites. A comparative study. Brain. 1991; 114(Pt 3):1297–1313.
   Google Scholar
• Oishi K, Mielke MM, Albert M, Lyketsos CG, Mori S. The fornix sign: a potential sign for Alzheimer’s disease based on diffusion tensor imaging. J Neuroimaging. 2012;22(4):365–374.
   PubMed Web of Science ®Google Scholar
• Fletcher E, Raman M, Huebner P, et al. Loss of fornix white matter volume as a predictor of cognitive impairment in cognitively normal elderly individuals. JAMA Neurol. 2013;70(11):1389–1395.
   PubMed Web of Science ®Google Scholar
• Mielke MM, Kozauer NA, Chan KC, et al. Regionally-specific diffusion tensor imaging in mild cognitive impairment and Alzheimer’s disease. Neuroimage. 2009;46(1):47–55.
   Web of Science ®Google Scholar
• Toda H, Hamani C, Fawcett AP, Hutchison WD, Lozano AM. The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. J Neurosurg. 2008;108(1):132–138.
   PubMed Web of Science ®Google Scholar
• Hamani C, Stone SS, Garten A, Lozano AM, Winocur G. Memory rescue and enhanced neurogenesis following electrical stimulation of the anterior thalamus in rats treated with corticosterone. Exp Neurol. 2011;232(1):100–104.
   PubMed Web of Science ®Google Scholar
• Smith GS, Laxton AW, Tang-Wai DF, et al. Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. Arch Neurol. 2012;69(9):1141–1148.
   PubMed Web of Science ®Google Scholar
• Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies. Am J Psychiatry. 2002;159(5):738–745.
   Web of Science ®Google Scholar
• Damoiseaux JS, Prater KE, Miller BL, Greicius MD. Functional connectivity tracks clinical deterioration in Alzheimer’s disease. Neurobiol Aging. 2012;33(4):828. e819–e830.
   Web of Science ®Google Scholar
• Hamani C, McAndrews MP, Cohn M, et al. Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann Neurol. 2008;63(1):119–123.
   PubMed Web of Science ®Google Scholar
• Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8(1):1–13.
   PubMed Web of Science ®Google Scholar
• Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988;24(4):637–639.
   Google Scholar
• Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141(11):1356–1364.
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Galik E, Steele C, et al. The General Medical Health Rating: a bedside global rating of medical comorbidity in patients with dementia. J Am Geriatr Soc. 1999;47(4):487–491.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–2314.
   PubMed Web of Science ®Google Scholar
• Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7(5):486–488.
   PubMed Web of Science ®Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435.
   PubMed Web of Science ®Google Scholar
• Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277.
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23(3):271–284.
   PubMed Web of Science ®Google Scholar
• Jack CR, Bernstein MA, Fox NC, et al. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685–691.
   PubMed Web of Science ®Google Scholar
• Jack CR, Bernstein MA, Borowski BJ, et al. Update on the magnetic resonance imaging core of the Alzheimer’s disease neuroimaging initiative. Alzheimers Dement. 2010;6(3):212–220.
   PubMed Web of Science ®Google Scholar
• Jagust WJ, Bandy D, Chen K, et al. The Alzheimer’s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6(3):221–229.
   PubMed Web of Science ®Google Scholar
• Benge JF, Balsis S, Geraci L, Massman PJ, Doody RS. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer’s disease? Dement Geriatr Cogn Disord. 2009;28(1):63–69.
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289(21):2819–2826.
   PubMed Web of Science ®Google Scholar
• Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol. 2003;60(6):843–848.
   PubMed Web of Science ®Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006(1):CD005593.
   Google Scholar
• Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–2414.
   PubMed Web of Science ®Google Scholar
• O’Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer’s research consortium study. Arch Neurol. 2008;65(8):1091–1095.
   PubMedGoogle Scholar
• Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1997;9(Suppl 1):173–176; discussion 177–178.
   PubMedGoogle Scholar
• Morris JC, Storandt M, McKeel DW, et al. Cerebral amyloid deposition and diffuse plaques in “normal” aging: evidence for presymptomatic and very mild Alzheimer’s disease. Neurology. 1996;46(3):707–719.
   Web of Science ®Google Scholar
• Berg L, McKeel DW, Miller JP, Baty J, Morris JC. Neuropathological indexes of Alzheimer’s disease in demented and nondemented persons aged 80 years and older. Arch Neurol. 1993;50(4):349–358.
   PubMedGoogle Scholar
• Delis DC, Kramer JH, Kaplan E, Ober BA, [Inventors]. California Verbal Learning Test – Second Edition. 2000.
   Google Scholar
• Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia. 1967;5:135–140.
   Web of Science ®Google Scholar
• Benedict R. Brief Visuospatial Learning Test-Revised, Professional Manual. Lutz, FL: Psychological Assessment Resources; 1997.
   Google Scholar
• Reitan RM. Validity of the Trail Making test as an indicator of organic brain damage. Perceptual Motor Skills. 1958;8:271–276.
   Google Scholar
• Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom Med. 2002;64(3):510–519.
   PubMed Web of Science ®Google Scholar
• Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F. Review of Alzheimer’s disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Alzheimers Res Ther. 2010;2(4):24.
   PubMed Web of Science ®Google Scholar
• Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001;286(17):2120–2127.
   PubMed Web of Science ®Google Scholar
• Smith GS, de Leon MJ, George AE, et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer’s disease. Pathophysiologic implications. Arch Neurol. 1992;49(11):1142–1150.
   Google Scholar
• Kadir A, Andreasen N, Almkvist O, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer’s disease. Ann Neurol. 2008;63(5):621–631.
   Web of Science ®Google Scholar
• Stefanova E, Wall A, Almkvist O, et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer’s disease. J Neural Transm. 2006;113(2):205–218.
   PubMed Web of Science ®Google Scholar
• Ihl R, Ferris S, Robert P, Winblad B, Gauthier S, Tennigkeit F. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer’s disease. Int J Geriatr Psychiatry. 2012;27(1):15–21.
   PubMed Web of Science ®Google Scholar
• Pozueta A, Rodríguez-Rodríguez E, Vazquez-Higuera JL, et al. Detection of early Alzheimer’s disease in MCI patients by the combination of MMSE and an episodic memory test. BMC Neurol. 2011;11:78.
   PubMed Web of Science ®Google Scholar
• Hardenacke K, Shubina E, Bührle CP, et al. Deep brain stimulation as a tool for improving cognitive functioning in Alzheimer’s dementia: a systematic review. Front Psychiatry. 2013;4:159.
   PubMedGoogle Scholar
• Hescham S, Lim LW, Jahanshahi A, et al. Deep brain stimulation of the forniceal area enhances memory functions in experimental dementia: the role of stimulation parameters. Brain Stimul. 2013;6(1):72–77.
   Web of Science ®Google Scholar
• Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369(4):341–350.
   PubMed Web of Science ®Google Scholar
• Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–321.
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014; 370(4):322–333.
   PubMed Web of Science ®Google Scholar
• Fontaine D, Deudon A, Lemaire JJ, et al. Symptomatic treatment of memory decline in Alzheimer’s disease by deep brain stimulation: a feasibility study. J Alzheimers Dis. 2013;34(1):315–323.
   PubMed Web of Science ®Google Scholar
• Kuhn J, Hardenacke K, Lenartz D, et al. Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s dementia. Mol Psychiatry. 2015;20(3):353–360.
   PubMed Web of Science ®Google Scholar
• Gillette-Guyonnet S, Andrieu S, Nourhashemi F, et al. Long-term progression of Alzheimer’s disease in patients under antidementia drugs. Alzheimers Dement. 2011;7(6):579–592.
   Web of Science ®Google Scholar
• Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42(1):85–94.
   PubMed Web of Science ®Google Scholar
• Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology. 2005;64(11):1860–1867.
   PubMed Web of Science ®Google Scholar